|Bid||1.4300 x 800|
|Ask||1.5600 x 1200|
|Day's range||1.3900 - 1.5300|
|52-week range||1.0200 - 1.9100|
|Beta (5Y monthly)||0.92|
|PE ratio (TTM)||N/A|
|Earnings date||10 Nov 2022 - 14 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||4.00|
AUSTIN, Texas, September 14, 2022--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees.
AUSTIN, Texas, September 06, 2022--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented three posters at the ERS International Congress 2022 that took place September 4-6th in Barcelona, Spain.
Potential Savara Inc. ( NASDAQ:SVRA ) shareholders may wish to note that the Independent Director, David Ramsay...